We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Research Sorting Out Risk Genes for Brain Disorders

By LabMedica International staff writers
Posted on 09 Mar 2017
Using targeted gene sequencing in a large cohort population, researchers have discovered genes associated with higher risk of neurodevelopmental-disorders (NDDs), with some of those genes showing statistical biases for autism. More...
The study provides new information about similarities and differences underlying various NDDs.

To identify and better understand gene-disrupting mutations related to NDDs, a team led by researchers of the laboratory of Evan Eichler, University of Washington Health Sciences/UW Medicine and Howard Hughes Medical Institute, conducted a large, international, multi-institutional study. More than 11,700 affected individuals and nearly 2,800 control subjects underwent targeted DNA sequencing of 208 suspected disease-risk genes, candidate genes that were chosen based on previously published studies. Samples were collected through the Autism Spectrum/Intellectual Disability 15-center network spanning 7 countries and 4 continents. An advantage of this collection is the ability to check back on a large fraction of cases in attempt to relate genetic results to clinical findings.

In their study population, the researchers associated 91 genes with risk of a NDD, including 38 genes not previously suspected. Based on some of the family studies, however, mutations even in two or more of the risk genes may not be necessary or sufficient to cause disease.

Of the 91 genes, 25 were linked with forms of autism without intellectual disability. The scientists also described a gene network that appeared to be related to high-functioning autism. Individuals with this form of autism have average to above average intelligence, but may struggle in learning to talk, interact socially, or manage anxiety and sensory overload. Additional findings suggest that less severe mutations may be behind autism that is not accompanied by intellectual disability. Also notable, although the overall numbers were low, was that several autism risk genes appeared predominantly in males, including some detected exclusively in males who had autism without intellectual impairment.

While observing that some genes were more closely associated with autism and others with intellectual or developmental impairments, the researchers found that most of the genes implicated were mutated in both conditions. This result reinforces previous studies indicating substantial overlap among NDDs in their underlying genetics and observable characteristics.

"Most of these genes are clearly risk factors for neurodevelopmental disorders in a broad sense," the researchers said, "But analysis of both the genetic and subsequent patient follow-up data did single out some genes with a statistical bias towards autism spectrum disorder, rather than an intellectual disability or developmental delay." By combining clinical and genetic data, the researchers observed patterns enabling them to begin to assess how some of the genes might function and how their disruption might lead to specific traits or symptoms.

The researchers also used Drosophila to investigate 21 genes to determine if any of the mutations disrupted a specific form of learning: habituation – growing accustomed to harmless stimuli. Problems with the neuronal mechanisms behind habituation are thought to account for some autism features, such as inability to filter sensory input. The Drosophila studies showed habituation deficits from several of the gene mutations under review, thereby providing additional evidence that they may have a role in cognitive function.

"The scientists are continuing this project and are eager to work with interested families," said University of Washington Prof. Raphael Bernier, clinical director of the Seattle Children's Autism Center. Families can contact the project team at rablab@uw.edu.

The study, by Stessman HAF et al, was published online February 13, 2017, in the journal Nature Genetics.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.